Femtobiomed
Latest round
- Series B
Last raised
- Feb 2019
Total raised
- $8M
Investors
- 4
About Femtobiomed
Femtobiomed Inc. is a biotechnology company specializing in innovative cell therapy solutions through advanced nonviral therapeutics and multiplexed engineering technologies, aimed at enhancing cell production yield and viability. Founded in 2011 and headquartered in Seongnam, South Korea, Femtobiomed Inc. delivers pioneering solutions in cell therapy and has undergone strategic advancements in its operations. In April 2024, Korea Investment Partners acquired 362,625 shares in Femtobiomed Inc.9 billion, in a PIPE transaction.. The company was founded by Sanghyun Lee, who has a history of entrepreneurial ventures in the biotechnology field. Femtobiomed specializes in innovative solutions for cell therapy, primarily focusing on advanced nonviral cell therapeutics and multiplexed cell engineering technologies. Its core products include the Decentralized Cell Therapy Manufacturing Device and the Electroporator, which utilize partitioned flow technology for simplified electroporation and bufferless transfection. This technology addresses significant challenges in the conventional viral cell and gene therapy (CAGT) sector by enhancing production yield and maintaining high cell viability in a cost-effective manner. FEMTOBIOMED targets a diverse client base, including researchers and clinicians within the biotechnology and pharmaceutical industries, primarily serving markets in North America, Europe, and select regions in Asia. Femtobiomed operates on a transactional model that primarily involves B2B interactions with researchers, healthcare institutions, and biotech companies.8 million. Clients engage in direct purchases of the Decentralized Cell Therapy Manufacturing Device and the Electroporator, alongside necessary consumable supplies. Pricing structures reflect the complexity and innovative nature of their offerings, fostering long-term collaborations and continual revenue generation. Femtobiomed plans to expand its product offerings with upcoming innovations in cell therapy technology, targeting a launch in the next 18 months. The company aims to penetrate new geographic markets, with a focus on expanding its presence in Europe and North America by the end of 2025.
Who invested in Femtobiomed
4 investors across 2 rounds
See all investors in Femtobiomed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Femtobiomed
Who invested in Femtobiomed?
Femtobiomed has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Femtobiomed raised?
Femtobiomed has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Femtobiomed last raise money?
Femtobiomed's most recent round on record is a Series B, in Feb 2019.
What does Femtobiomed do?
Femtobiomed is a biotechnology company.
Where is Femtobiomed headquartered?
Femtobiomed is headquartered in Gyeonggi-do, South Korea.
Which VCs invest in companies like Femtobiomed?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Femtobiomed's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Femtobiomed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.